Fatty Acid Synthase

Denifanstat (FASN-IN-2) is a FASN inhibitor with selective and oral activity. Denifanstat has been used in studies of steatohepatitis. Cost effective and quality assured.

<p>PF429242 dihydrochloride can reversibly inhibit S1P (IC50 of 175 nM).</p>

trans-C75 ((±)-C75) is an enantiomer of C75. C75 is an inhibitor of fatty-acid synthase (FASN).

FASN-IN-3 is an inhibitor of fatty acid synthase (FASN).

CTL-12, a fatty acid synthase (FASN) inhibitor (IC50: 2.5 μM), induces apoptosis and disrupts the cell cycle at the Sub-G1/S phase.

Fasnall HCl is a selective FASN inhibitor that acts through its co-factor binding sites.

IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).

FASN-IN-4 tosylate: Fatty acid synthase inhibitor, IC50 10 nM; blocks SARS-CoV-2, EC50 18.6 nM.

<p>Betulinditosylate is a derivative of Betulin, which functions as an SREBP inhibitor.</p>

FASN/SCD-IN-1 is a Silybin derivative and an orally active inhibitor of fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In vitro, FASN/SCD-IN-1 demonstrates the ability to inhibit lipid deposition, reduce the transcription levels of FASN and SCD, and exhibits antioxidant, anti-inflammatory, and antifibrotic activities. It shows significant hepatoprotective effects in rat models of acute liver injury and improves pathological features such as steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative-associated steatohepatitis (MASH). FASN/SCD-IN-1 can be used for MASH research.

CTL-06, a Fatty Acid Synthase (FASN) inhibitor with an IC50 of 3 μM, induces apoptosis, while CTL-12 impedes cell cycle progression in the Sub-G1/S phase and

MTB-9655 inhibits ACSS2 with 3.8 nM IC50, useful in research of viral, metabolic, neuropsychiatric diseases, inflammation, and cancer.

<p>A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).</p>

FASN Protein, Human, Recombinant (His) is expressed in E.

Anti-FASN Antibody (6U56) is an antibody targeting FASN. Anti-FASN Antibody (6U56) can be used in ELISA, IF, FCM.

GSK2194069: Fatty acid synthase inhibitor, β-keto reductase-specific, IC50 7.7 nM, hampers cancer cell proliferation.

<p>BI 99179 is a selective and potent inhibitor of type I fatty acid synthase (FAS), a tool compound for targeting FAS for cancer research.</p>

FASN Protein, Mouse, Recombinant (His) is expressed in E.

FT113 is a novel potent inhibitor of fatty acid synthase (fasn, IC50 : 213 nM),and exhibits anti-cancer activity

Fas C-Terminal Tripeptide Acetate shows inhibitory activity of Fas/FAP-1 binding.